-transparent.png){kind=logo}
OBJECTIVE To assess the safety and efficacy of a second course of treatment with a murine monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in active rheumatoid arthritis (RA). METHODS In an open-label study, 8 patients who had previously received a course of anti-ICAM-1 MAb received a second course. RESULTS The second course of therapy was associated with adverse effects suggestive of immune complex formation. Such adverse effects were not seen during the initial course of therapy. Clinical efficacy associated with the second course of therapy was less than that observed in the first course. CONCLUSIONS Repeated courses of therapy with a murine MAb to ICAM-1 would probably not be a useful therapeutic strategy in patients with RA, probably because of its immunogenicity.
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
July 1994,
Arthritis and rheumatism,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
October 2004,
Tissue antigens,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
January 1995,
Ciba Foundation symposium,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
November 1993,
Scandinavian journal of immunology,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
October 1997,
Stroke,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
January 2000,
Clinical and experimental rheumatology,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
October 1993,
Cardiovascular surgery (London, England),
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
August 1993,
Transplantation,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
July 1993,
Clinical immunology and immunopathology,
A F Kavanaugh, and
H Schulze-Koops, and
L S Davis, and
P E Lipsky
February 2011,
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,
